Identity
What is DSIP?
A nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

Research reference · Cognition & Sleep
Delta sleep-inducing peptide (DSIP, emideltide) is a nonapeptide isolated in the 1970s. Small human sleep studies from the 1980s and 1990s reported mixed results.
Published by Elevated Pharma ·
Identity
A nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.
Research context
Early isolation work defined the sequence; small clinical studies in insomnia found weak or inconsistent effects.
Evidence boundary
The limited, mixed human literature does not establish benefit or safety.
U.S. status · November 7, 2026
FDA’s compounding advisory committee voted 7–6 (one abstention) against adding emideltide (DSIP) to the 503A bulks list on July 24, 2026, the only one of seven peptides it turned down. It is not covered by the October 2026 HHS interim policy.
FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).
Read the sourceKey studies
Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.
Search all 408 PubMed records for DSIP · Counts and selections checked November 7, 2026.
Reference identifiers
Database identity describes the reference substance, not any specific material or lot.
Official & primary sources
Citation does not imply an Elevated Pharma partnership or endorsement.